Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of motixafortide plus G-CSF for hematopoietic stem cell mobilization in multiple myeloma
CTR20242490Phase 3Active
- Sponsor
- BioLineRx Ltd.
- Start
- Dec 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of motixafortide, filgrastim, sponsored by BioLineRx Ltd.. Started Dec 2025; status: active.
02
Drugs
motixafortidefilgrastim
Beyond the preview
Go deeper on CTR20242490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242490.